Journal
AMERICAN HEART JOURNAL
Volume 233, Issue -, Pages 86-91Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.ahj.2020.12.007
Keywords
-
Categories
Funding
- NIH [2R01 HL127661-05]
- Bayer
- Boehringer Ingelheim
- AstraZeneca
- Department of Veterans Affairs, Veter-ans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development (Washington, DC, USA) [BX-000282-05]
- Novartis
- Amgen
- Bristol-Myers Squibb
- Merck
- Mario Family Award
- Translating Duke Health Award
- Duke Medicine Chair's Award
Ask authors/readers for more resources
Nine randomized clinical trials involving 60,914 patients with type 2 diabetes showed that the use of SGLT2 and dual SGLT1/2 inhibitors can improve cardiovascular and kidney outcomes.
In this report, we aim to provide an updated meta-analysis of the sodium-glucose cotransporter 2 (SGLT2) inhibitors trial data with the new trial data on sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor. We searched Medline, Cochrane library, and Embase databases for randomized clinical trials comparing cardiovascular and kidney outcomes between SGLT2 and dual SGLT1/2 inhibitors and placebo. Nine randomized clinical trials with a total of 60,914 patients with type 2 diabetes were included. In patients with type 2 diabetes, the use of SGLT2 and dual SGLT1/2 inhibitors improves the cardiovascular and kidney outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
